Open-label,Non-randomised,Multicentre,Phase I Study to Assess the Pharmacokinetics, Safety & Tolerability of Osimertinib Following a Single Oral 80mg Dose to Patients w/ Adv Solid Tumours & Normal Renal Function or Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 07 Jun 2017 Planned End Date changed from 1 Apr 2018 to 28 Aug 2018.
- 07 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 28 Aug 2018.
- 07 Jun 2017 Status changed from not yet recruiting to recruiting.